Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
Putting resources into Yourself: Self-awareness Techniques - 2L.A.'s most famous midcentury home, the Stahl House, is on the market for the 1st time, at $11K per square foot: See inside
- 3Distributed storage Answers for Information Reinforcement
- 4Decrease in Home Buy Credits and Home loan Renegotiating Rates: An Outline of Latest things
- 5Consume Fat Quick: 10 Demonstrated Activities for Ideal Outcomes
- Charlotte faith leaders hold interfaith forum on Black and Palestinian solidarity
- 2025 Arctic League telethon raises more than $39k
- Top 20 Style Brands for Pioneers
- Role reversal: Ukraine moves training home and exports the lessons abroad
- WHO suspends Gaza medical evacuations after contractor killed by Israeli troops
- MacArthur Foundation awards $100M to outbreak surveillance network, a boost amid global health cuts
- The most effective method to Really Adjust Hypothesis and Practice in Your Brain science Studies
- South African army arrive in crime hotspots to help tackle gangs
- SpaceX shatters its rocket launch record yet again — 165 orbital flights in 2025
